Cargando…
Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors’ molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830511/ https://www.ncbi.nlm.nih.gov/pubmed/33467460 http://dx.doi.org/10.3390/jpm11010048 |
_version_ | 1783641432132681728 |
---|---|
author | Oberndorfer, Felicitas Moling, Sarah Hagelkruys, Leonie Annika Grimm, Christoph Polterauer, Stephan Sturdza, Alina Aust, Stefanie Reinthaller, Alexander Müllauer, Leonhard Schwameis, Richard |
author_facet | Oberndorfer, Felicitas Moling, Sarah Hagelkruys, Leonie Annika Grimm, Christoph Polterauer, Stephan Sturdza, Alina Aust, Stefanie Reinthaller, Alexander Müllauer, Leonhard Schwameis, Richard |
author_sort | Oberndorfer, Felicitas |
collection | PubMed |
description | Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors’ molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the clinical feasibility of molecular profiling and its potential impact on treatment decisions. Tumor specimens underwent molecular profiling (testing for genetic alterations, (immune-)histological examination of lymphovascular space invasion (LVSI), and L1CAM) as part of the clinical routine and were classified according to the European Society for Medical Oncology (ESMO) classification system and to an integrated molecular risk stratification. Shifts between risk groups and potential treatment alterations are described. A total of 60 cases were included, of which twelve were excluded (20%), and eight of the remaining 48 were not characterized (drop-out rate of 16.7%). Molecular profiling revealed 4, 6, 25, and 5 patients with DNA polymerase-epsilon mutation, microsatellite instability, no specific molecular profile, and TP53 mutation, respectively. Three patients had substantial LVSI, and four patients showed high L1CAM expression. Molecular profiling took a median of 18.5 days. Substantial shifts occurred between the classification systems: four patients were upstaged, and 19 patients were downstaged. Molecular profiling of EC specimens is feasible in a daily routine, and new risk classification systems will change treatment decisions substantially. |
format | Online Article Text |
id | pubmed-7830511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78305112021-01-26 Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data Oberndorfer, Felicitas Moling, Sarah Hagelkruys, Leonie Annika Grimm, Christoph Polterauer, Stephan Sturdza, Alina Aust, Stefanie Reinthaller, Alexander Müllauer, Leonhard Schwameis, Richard J Pers Med Article Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors’ molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the clinical feasibility of molecular profiling and its potential impact on treatment decisions. Tumor specimens underwent molecular profiling (testing for genetic alterations, (immune-)histological examination of lymphovascular space invasion (LVSI), and L1CAM) as part of the clinical routine and were classified according to the European Society for Medical Oncology (ESMO) classification system and to an integrated molecular risk stratification. Shifts between risk groups and potential treatment alterations are described. A total of 60 cases were included, of which twelve were excluded (20%), and eight of the remaining 48 were not characterized (drop-out rate of 16.7%). Molecular profiling revealed 4, 6, 25, and 5 patients with DNA polymerase-epsilon mutation, microsatellite instability, no specific molecular profile, and TP53 mutation, respectively. Three patients had substantial LVSI, and four patients showed high L1CAM expression. Molecular profiling took a median of 18.5 days. Substantial shifts occurred between the classification systems: four patients were upstaged, and 19 patients were downstaged. Molecular profiling of EC specimens is feasible in a daily routine, and new risk classification systems will change treatment decisions substantially. MDPI 2021-01-15 /pmc/articles/PMC7830511/ /pubmed/33467460 http://dx.doi.org/10.3390/jpm11010048 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Oberndorfer, Felicitas Moling, Sarah Hagelkruys, Leonie Annika Grimm, Christoph Polterauer, Stephan Sturdza, Alina Aust, Stefanie Reinthaller, Alexander Müllauer, Leonhard Schwameis, Richard Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data |
title | Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data |
title_full | Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data |
title_fullStr | Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data |
title_full_unstemmed | Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data |
title_short | Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data |
title_sort | risk reclassification of patients with endometrial cancer based on tumor molecular profiling: first real world data |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830511/ https://www.ncbi.nlm.nih.gov/pubmed/33467460 http://dx.doi.org/10.3390/jpm11010048 |
work_keys_str_mv | AT oberndorferfelicitas riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT molingsarah riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT hagelkruysleonieannika riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT grimmchristoph riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT polterauerstephan riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT sturdzaalina riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT auststefanie riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT reinthalleralexander riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT mullauerleonhard riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata AT schwameisrichard riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata |